SecBot SecBot
8-K ·Filed Oct 15, 2026

MBIO

MUSTANG BIO, INC.
BEARISH
Impact 6/10
Horizonmonths Processed11d 12h ago SEC0001104659-26-116233
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Monitor MBIO's bid price closely for any sustained recovery above $1.00. A reverse stock split is the most likely cure, but the market will assess whether the split's terms and shareholder approval timeline. Delisting would severely impair liquidity and access to capital markets.

DirectionBearish
Confidencehigh
Horizonmonths
Latest settled — T+5d
MBIO ▼ -1.70% at T+5d
SHORT call ✓ call won +1.70% · α vs SPY +1.27% · entry $0.3764 → $0.3700
Next anchor: T+20d in 16d
Entry = T+0 close
Oct 15, 2026
via day close
T+1d
-0.90%
call +0.90% · α +1.33%
$0.3730
settled 11d ago
T+5d
-1.70%
call +1.70% · α +1.27%
$0.3700
settled 5d ago
T+20d
Pending
in 16d
T+60d
Pending
in 3mo

Price Chart

Loading chart...

Executive Summary

Mustang Bio received Nasdaq notice that its stock failed to meet the $1.00 minimum bid price by the initial 180-day deadline (Oct 12, 2026). Nasdaq granted an additional 180-day grace period through April 12, 2027, to regain compliance. The company may pursue a reverse stock split if needed, but delisting risk persists if compliance is not achieved.

Key Facts

  • Bid price closed below $1.00 for 30 consecutive business days as of April 15, 2026
  • Initial 180-day grace period expired October 12, 2026 without compliance
  • Nasdaq granted second 180-day grace period through April 12, 2027
  • Company may effect a reverse stock split to regain compliance
  • Failure to cure by April 12, 2027 will result in delisting notice

Financial Impact

Delisting risk for MBIO common stock; no specific dollar amounts provided in filing

stock pricelisting status

Risk Factors

  • Failure to regain compliance by April 12, 2027 triggers delisting
  • Reverse stock split may not be approved or may not sustain compliance
  • Appeal process does not pause trading suspension

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-116233
Document: 0001104659-26-116233-index-headers.html0001104659-26-116233
Document: 0001104659-26-116233-index.html0001104659-26-116233
Document: 0001104659-26-116233.txt0001104659-26-116233
2 reports for MBIO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MBIO — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
8-K
BEARISH ★ 6/10
$0.3764 $0.3700▲ +1.70%▲ +1.27%$0.3600 (+4.36%)
Apr 17, 2026
27w ago
8-K
BEARISH ★ 8/10
$0.7400 $0.7600▼ −2.70%▼ −1.79%$0.3600 (+51.35%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 4h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 15, 2026